This case describes a 75-year-old man who developed pulmonary fibrosis. The onset of symptoms occurred three months after starting mexiletine. A computerized tomogram obtained eight months after initiating mexiletine documented findings consistent with chronic pulmonary fibrosis. The patient died from intractable respiratory difficulties 13 months after beginning mexiletine therapy. To date, there have been three cases of pulmonary fibrosis in patients receiving mexiletine spontaneously reported to the manufacturer.
Get full access to this article
View all access options for this article.
References
1.
ConoscentiCSWagshulFBierAMexiletine associated rapid progression of interstitial pneumonitis (abstract). Am Rev Respir Dis1986; 133 (4 pt 2):A317.
2.
CooperJADWhiteDAMatthayRA. Drug induced pulmonary disease. Part 2: Noncytotoxic drugs. Am Rev Respir Dis1986; 133: 488–505.
3.
AhmadMTomashefskiJF. Drug induced pulmonary disease. In: BaumGLWolinskyE, eds. Textbook of pulmonary diseases. Boston: Little, Brown, 1983: 727–39.
4.
KellyHW. Drug induced pulmonary disorders. In: YoungLYKoda-KimbleMA, eds. Applied therapeutics. The clinical use of drugs. Vancouver, WA: Applied Therapeutics, 1988: 437–45.
5.
Van NattaBLazarusMLiC. Irreversible interstitial pneumonitis associated with tocainide therapy. West J Med1988; 49: 91–2.
6.
SteinMGDemarcoTGamsuGComputed tomography: Pathologic correlation in lung disease due to tocainide. Am Rev Respir Dis1988; 137: 458–60.
HornHRHadidianZJohnsonJLSafety evaluation of tocainide in the American emergency use program. Am Heart J1980; 100: 1037–40.
10.
JonesJK. Adverse drug reactions in the community health setting: Approaches to recognizing, counseling and reporting. Fam Community Health1982; 5: 58–67.
11.
NaranjoRBustoSSellersJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–45.
